After speaking to a practicing hematologist and emergency medicine doctor at a leading medical institution, Piper Jaffray analyst Danielle Brill is "incrementally more bullish" on both GlycoMimetics (GLYC) and Global Blood Therapeutics (GBT). The former has pivotal Phase 3 data with rivipansel expected in July and the latter is in the process of submitting a new drug application for voxelotor via the accelerated approval pathway, Brill tells investors in a research note. Further, the analyst says feedback from the expert reaffirmed her neutral outlook for Bluebird Bio's (BLUE) LentiGlobin. The hematologist expects rivipansel to be successful in the Phase 3 trial and anticipates use for most acute sickle cell disease crises requiring provider intervention, according to Brill. Further, she was surprised to hear how enthusiastic the expert was about voxelotor.